Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 897

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 897
---
 Company. The Company does not maintain ownership in any subsidiaries and therefore does not consolidate any other entities within the presented financial statements.

#### 2. Summary of Significant Accounting Policies

#### Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant estimates and assumptions reflected within these financial statements include, but are not limited to, prepaid and accrued research and development expenses, including those related to contract research organizations, or CROs, contract development manufacturing organizations, or CDMOs, and other third-party vendors, and the valuation of the Company’s common stock and stock-based awards. Changes in estimates are recorded in the period in which they become known.

<div align='center'>F-96</div>

TABLE OF CONTENTS

2. Summary of Significant Accounting Policies (continued) Concentration of Credit Risk and of Significant Suppliers The Company’s cash, cash equivalents and short-term investments represent potential concentrations of credit risk. The Company deposits its cash and cash equivalents in financial institutions in amounts that may exceed federally insured limits, has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The short-term investments consist of U.S. Treasury Notes which the Company believes represent minimal credit risk. The following table presents information about the Company’s significant suppliers:

| ​        
 ​        | ​ 
 ​ | ​ 
 ​ | For the Year EndedDecember 31, 
 2023                           |   |     |   | ​ | ​ | 2022 |   |     |   | ​ 
 ​ | ​ 
 ​ | As ofDecember 31,    
 2023                 |   |     |   | ​ | ​ | 2022 |   |     |   | ​ 
 ​ |
|:---------|:--|:--|:-------------------------------|:--|:----|:--|:--|:--|:-----|:--|:----|:--|:--|:--|:---------------------|:--|:----|:--|:--|:--|:-----|:--|:----|:--|: